JOP20240054A1 - الأجسام المضادة لناقل أحادي كربوكسيلات بشري 1 واستخداماتها - Google Patents

الأجسام المضادة لناقل أحادي كربوكسيلات بشري 1 واستخداماتها

Info

Publication number
JOP20240054A1
JOP20240054A1 JOJO/P/2024/0054A JOP20240054A JOP20240054A1 JO P20240054 A1 JOP20240054 A1 JO P20240054A1 JO P20240054 A JOP20240054 A JO P20240054A JO P20240054 A1 JOP20240054 A1 JO P20240054A1
Authority
JO
Jordan
Prior art keywords
antibodies
human
monocarboxylate transporter
mct1
human monocarboxylate
Prior art date
Application number
JOJO/P/2024/0054A
Other languages
Arabic (ar)
English (en)
Inventor
Joseph Benjamin Granger
Frank Charles Dorsey
Kira Vladimirovna Rubtsova
Oliver Schroeder
Wei Wang
Original Assignee
Immunometabolism Dev Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunometabolism Dev Company Llc filed Critical Immunometabolism Dev Company Llc
Publication of JOP20240054A1 publication Critical patent/JOP20240054A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JOJO/P/2024/0054A 2021-09-14 2024-03-13 الأجسام المضادة لناقل أحادي كربوكسيلات بشري 1 واستخداماتها JOP20240054A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163261177P 2021-09-14 2021-09-14
US202163272903P 2021-10-28 2021-10-28
PCT/US2022/076400 WO2023044325A1 (en) 2021-09-14 2022-09-14 Human monocarboxylate transporter 1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
JOP20240054A1 true JOP20240054A1 (ar) 2024-03-13

Family

ID=83558178

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2024/0054A JOP20240054A1 (ar) 2021-09-14 2024-03-13 الأجسام المضادة لناقل أحادي كربوكسيلات بشري 1 واستخداماتها

Country Status (16)

Country Link
US (1) US11987624B2 (enExample)
EP (1) EP4402172A1 (enExample)
JP (2) JP7753348B2 (enExample)
KR (1) KR20240053656A (enExample)
AU (1) AU2022347031B2 (enExample)
CA (1) CA3230072A1 (enExample)
CL (1) CL2024000733A1 (enExample)
CO (1) CO2024003042A2 (enExample)
CR (1) CR20240133A (enExample)
DO (1) DOP2024000049A (enExample)
EC (1) ECSP24020235A (enExample)
IL (1) IL311253A (enExample)
JO (1) JOP20240054A1 (enExample)
MX (1) MX2024003115A (enExample)
TW (1) TWI842088B (enExample)
WO (1) WO2023044325A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3087259A1 (en) 2018-01-05 2019-07-11 Immunext, Inc. Anti-mct1 antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132813A1 (en) 2001-05-30 2004-07-08 Brooks George A. Glycerol-lactate esters for use as an energy supplement during exercise and recovery
WO2012178173A1 (en) 2011-06-24 2012-12-27 Centrose, Llc Extracellular targeted drug conjugates
GB201418626D0 (en) 2014-10-20 2014-12-03 Univ London Queen Mary Method
CA3087259A1 (en) * 2018-01-05 2019-07-11 Immunext, Inc. Anti-mct1 antibodies and uses thereof

Also Published As

Publication number Publication date
TWI842088B (zh) 2024-05-11
KR20240053656A (ko) 2024-04-24
WO2023044325A1 (en) 2023-03-23
CR20240133A (es) 2024-05-06
MX2024003115A (es) 2024-06-19
CL2024000733A1 (es) 2024-08-30
IL311253A (en) 2024-05-01
JP7753348B2 (ja) 2025-10-14
AU2022347031B2 (en) 2026-07-23
TW202330602A (zh) 2023-08-01
CA3230072A1 (en) 2023-03-23
DOP2024000049A (es) 2024-06-16
JP2026004435A (ja) 2026-01-14
WO2023044325A9 (en) 2024-04-25
ECSP24020235A (es) 2024-06-28
CO2024003042A2 (es) 2024-03-18
JP2023542639A (ja) 2023-10-11
US20230111363A1 (en) 2023-04-13
AU2022347031A1 (en) 2024-03-14
US11987624B2 (en) 2024-05-21
EP4402172A1 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
JOP20210071A1 (ar) أجسام مضادة مثبّتة trem2
JOP20220204A1 (ar) الأجسام المضادة لـ cd19 البشرية
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
SA521420953B1 (ar) بروتين ربط مولد ضد مضاد لـمولد ضد ظهاري ذو 6 أغشية انتقالية من البروستاتا 1
JOP20230312A1 (ar) أجسام مضادة لـ ccr8 واستخداماتها
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
CY1124153T1 (el) Αντισωματα και πολυπεπτιδια που κατευθυνονται εναντι cd127
MY205789A (en) Anti-gdf15 antibodies, compositions and methods of use
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EP4248996A3 (en) Anti-trem2 antibodies and methods of use thereof
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
EA201100694A1 (ru) Антитело к cd38 человека и его применение
UA112416C2 (uk) Антитіло до fap і способи його застосування
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
EA200800812A1 (ru) Композиции антитела против cd3
JOP20230311A1 (ar) أجسام مضادة لـ sirp-ألفا
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
EA202190235A1 (ru) Антитела к cd33 и способы их применения
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
EA202091747A1 (ru) Составы антитела b7-h4
MX2023014154A (es) Anticuerpos anti-ccr8.
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
MX2024001644A (es) Anticuerpos contra el receptor alfa de la interleucina-4 humana.
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ